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We studied the response of a human squamous cell 
carcinoma cell line, SCC-12F, to human complement 
attack and found that the cells were completely 
resistant to complement lysis. In the absence oflysis, 
there was significant C3 deposition and CSb-9 dep-
osition on the cells. Removal of the lipid-linked 
complement regulatory proteins CD59 and decay-
accelerating factor (DAF) by treatment of the cells 
with phosphatidylinositol-specific phospholipase C 
(PIPLC) resulted in increased C3b and CSb-9 deposi-
tion on the cells and a slight increase in cell death. 
Treatment of the cells with complement caused them 
C omplement deposition is found in many skin dis-eases including pemphigus, builous pemphigoid, porphyria cutanea tarda, cutaneous lupus, dermato-myositis, and necrotizing vasculitis (Tagmni, 1992) . Complement is known to play a major role in host 
defense against microorganisms, but its precise role in most auto-
immune and inflammatory diseases of the skin is not clear (Whaley 
et al, 1993). 
The complement system consists of 14 proteins in addition to 
various inhibitors and regulat9ry proteins and can be activated via 
two pathways, one usually requiring specific antibodies (classical 
pathway) and one that is generally independent of antibody (alter-
native pathway; Mayer, 1978). Both pathways end il1 a final 
common pathway of membrane attack involving the formation of a 
transmembrane channel by the terminal complement protems CS, 
C6, C7, C8, and C9 (Mayer el a/, 1981). 
The presence and distt·ibution of complement prote ins and 
complem ent protein fragments in skin biopsy specimens has been 
central to the diagnosis and classification of autoimmune cutaneous 
disease. In the case of autoimmune blistering diseases , complement 
deposi tion is found either on the keratilwcyte membrane or 
adjacent to keratil10cytes within the basement membrane zone 
Qordan, 1991). 
Despite the many studies showing the deposition of complement 
proteins in cutaneous disease, the actual pathogenic role of the 
complement system in human disease is not always clear. One 
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to release membrane vesicles containing the terminal 
complement proteins. In addition, complement in-
duced SCC-:-12F to produce significant amounts of 
prostaglandin F 2 a (PGF2 a>. We conclude that CD59 
and DAF are important in the resistance of SCC-12F 
to comple1nent and that these cells produce mem-
brane vesicles and PGF2 ._. in response to complement 
attack. These responses, in the absence of cell death, 
may be important in the pathogenesis of inflamma-
tory skin disease in which complement is deposited. 
Key IVOJ'ds: kevatinocyteli11jlatmtJatiortleicosinoid. J Invest 
Derm.atol 109:39-45, 1997 
approach to defining the functional ro le of complement in skin 
disease is to use a.n.imaJ models. Liu eta/ (1995) have recently shown 
that rabbit antibodies against the mouse homolog of the bullous 
pemphigoid antigen BP180 induce pemphigoid-like bullae in nor-
mal mice, but these antibodies \'Vill not mduce bullae in mice that 
are either congenitally deficient i.n CS or in mice ch emically 
depleted of C3 with cobra venom factor. Thus the terminal 
complement proteins are required to induce disease in this model. 
Another approach to defi.ning the functional ro le of complement in 
skin disease is to study the effects of complement on skiJ1 cells ;,, 
11itro. Several studies have demonstrated that serum from patients 
with vitiligo has anti-melanocyte antibodies and tl1at these antibod-
ies are capable of mediating complement-induced and cell-medi-
ated cytotoxicity (Norris ct a/, 1988; Cui et a/, 1993) . There has 
been one study on the ability of complement to lyse keratinocytes. 
These authors found that keratinocytes are remarkably resistant to 
complement lysis but that treatment of keratinocytes with the 
protein synthesis inhibitor cyclohexiJ11ide increased complement-
mediated cytolysis (Norris el nl, 1985). 
Cells have developed two general techniques for evading com-
plement-mediated membrane damage. One is the presence of 
membrane-bound complem ent inhibitors such as complement re-
ceptor 1, decay-accelerating factor (DAF), and CD59 (HolguiJ1 and 
Parker, 1992; Nicholson-Weller, 1992; Ross, 1992). DAF m1d 
CD59 are both glycan phosphatidylinositol-linked, meanmg that 
they associate with the m embrane via a lipid anchor bound 
covalently to the carboxyl terminus of the protein (Low, 1989). In 
addition to these il1hibitory surface molecules, cells ha ve the ability 
to remove complement channels fi:om their surface by either 
endocytosis or membrane vesiculation (Morgan et a/, 1987; Shil1 
and Carney, 1988). T his process is highly selective, because the 
damaged area of membrane is removed but the vast majority of 
membrane is unaffected (Morgan et a/, 1987) . 
In addition to repair of tl1e damaged membrane, cells w1der 
0022-202X/97 /$10.50 • Copyright © 1997 by T he Society for Investigative Dermatology, Inc. 
39 
40 WH ITLOW AND K LEIN 
attack by comp le m ent also synthesize and release arachidonic acid 
m eta bo lites, release cytokines , and de monstrate increased cell 
division (Morgan, l. 993). T hese no nle thal effects of complem en t 
h ave not been studied in keratinocytes; however, in the majority of 
skin diseases in which complem en t is deposited, cell death is not a 
prominent histologic feature. T here fore , these no nl ytic effects pl ay 
a poten tia lly important role in the pathogenesis of autoimmune ski11 
disease. 
T he purpose of this investigation was to study th e effects of 
complem ent on a squ amous cell carcin om a cell lin e , SCC-12F. T he 
SCC-12F cell line is clonally derived fi·om a squ am o us cell carci-
noma of th e facial epidermis and is phenotypically sim.ilar to normal 
human keratinocytes based o n its abili ty to form cornified enve-
lopes and its growth in sem.i-solid medium (Rheinwald and Beck-
ett, "1980, 1 981 ) . Th us the SCC-12F cells provide a m odel system 
to study the response of human keratinocytes to complem ent. In 
th.is study we examin ed the nonl ytic ;111d lytic effects of compl ement 
on SCC-12F and studied d1e e ffects of removing the complement 
regulatory proteins DAF and CD59. 
MATEIUALS AND MET HODS 
CeU Culture Stock cul tures of SCC-12F ce ll s (kindly provided by Dr. 
James R.heinwald, Dana-Farber Cancer R.csea rch Institu te, Boston , MA) 
were grown on a mitomycin C (Sigma, St. Lo uis , MO)-n·eatcd feeder laye r 
of murine 3T3 ce lls (A.merica11 Type C ul ture Collection, R ockville , MD) in 
Dulbccco's modified Eagle's medium (DMEM) high glucose:DMEM/F12, 
3:1 ratio (1.4 mM calcium and 0.848 mM magnesium) containing antibiotics 
(50 U pcnicill.in per ml and 50 U streptomyc in pe r ml; Life Technologies, 
Ga ithe rsburg, MD) 10% fetal bovine serum (Gemini , C llabasas , CA), and 
0 .5 f-l.g hydrocorti sone per ml (Calbiochcm, La J o ll a, CA). After estab]jsh-
ment of the SCC-1 2F cells in culture, they were passaged by spl itting the 
cul ture 1:3 in the absence of mouse 3T3 ce lls. 
Production of SCC-12F Plasma Membrane Vesicles SCC-12F 
membranes were gem:rated by a variation of the tcc hn.ique ofDabclsteen cl 
nl (1980). Confluen t SCC-12F cell s in a 75-cm2 flask were washed two 
times with Phosphate bulfered saline (PBS) and then incubated with 15 ml 
of fres hl y made 25 inM formaldehyde (S igma, St. Louis, MO), 2 mM 
dith.iothreito l (Sigma, St. Lou.is, MO) at 37°C for 2 h. T he supernatant was 
centrifuged fo r 15 min at 412,000 X ,~ i11 an Optima TL ultracentrifuge 
(Beckman , Carlsbad, CA). T he pellet was resuspended in PBS for immu-
nization of the rabbits. 
Imntunization Protocol Antibodies to the vesicles were raised in two 
2- to 3-kg wh.ite rabbits . One milliliter (454 f-l.g) of vesicle pro tein was 
mixed with ·1 .0 ml of Freund' s complete adjuvant. After collection of 
prcirnn1unization scnn11, the an i1naJs were injected subcuta neously at 
mul tiple sites (tota l antigen injected, 1 .0 ml con tai ning 227 f-l.g of vesicle 
protein per rabbi t). Rabbits were given a booster injection (154 !J-g per 
animal) in Freund 's incomple te adjuvan t 2 wk later. Animals were bled 
weckJy. Ser<~ ti·o m bleeds 3, 4, and 5 from one rabb.it were pooled a11d 
purified with the Affi-Gcl prote in A-agarose (Bio- Llad, luchmond, CA) as 
sp eci fied by the manufacture r. T his purified antibody was then used for 
further experiments. 
F luorescence-Activated C eU Sorter (FACS) Analysis For FACS 
analysis using mo use monoclonal an tibod ies, one we ll of a six -well plate o f 
SCC-1 2F ce ll s was washed wi th PBS and trea ted with 1.0 ml of primary 
mouse monoclon al antibody at 5 f-l.g per mi. Cells were incuba ted on ice for 
30 min and washed with PBS, and a I :20 dilution o f chc secondary ;mtibody 
[ph ycoe rythr in- labe led ra bbit anti- mouse l gG (Cal tag, South San Francisco, 
CA)) w:.1s added. Cells were incubated for an :Jdditional 30 m.in on .icc, 
washed with PBS, and fi xed with 4'X, paraformaldchyde ("I .0 ml per we ll ) fo r 
1 0 min at room temperature. Cells were removed from the plate with a cell 
dissociation solution (Sigma, St. Louis, MO) and subjected to FACS 
analysis. T he following primary mouse monoclonal an tibodies were used: 
anti-C3 b, C5G (lida ct a/, 1987); an ti-OAF, a mix ture of IA1 0 plus lll-1 6 
(Kinoshi ta et nl, "1985); anti-CD 59, MEM-43 [a generous gift from Dr. Irena 
Stefan ova (W h.irlow ct nl, 1990)]; an ti-C9 neoantigcn (Quidcl, San Diego, 
CA). Control primary antibody was Hb-5 [an anti-complement receptor 2 
(CR.2) IgG, purified fi·om the THB-5 ce ll !.inc purchased fro m American 
Type T issue C ulture Collection, R.ockvi ll e, MD, and purifi ed as described 
(Ncmcrow er nl, 1985)]. 
For FACS using pre-immune :md immune rabbit sera, one well of a 
six-well pl :1te of SCC-12F cells was washed with PBS and treated with 1.0 
ml of a 1:10 dilu tion of pre-immune o r irnmum: rabbit serum . Cell s were 
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incubated on icc fo r 30 m.in and washed w ith PUS , and a 1 :20 dilution of the 
secondary antibody (phycoerythrin-labeled r<~bbit :mti-rabbi t (Ca ltag)] was 
added. Cell s were incubated for an additional 30 min on ice, washed wirl1 
PBS, and fixed with 4% para formald ehyde {1 .0 mil well) for 10 min at room 
temperature. Cell s were removed fro m the plate with cell dissociation 
solu tion (Sigma, St. Louis, MO) and subjec ted to FACS analysis. 
Subcellular Fractionation of SCC-12F SCC- L2F were removed ll-01n 
the 75-mm2 flas ks wi th dissociation so lu tion (Sigma, St. Louis, MO). C ells 
were washed and resuspended to a final concentration of 2 X 1 07 cells pe r 
ml in homogenization bulfcr (0.25 M sucrose, 20 mM 1-!.EPES, 0.5 mM 
ethylene glycol-bis(/3-aminoe th yl ether)- N,N,N' ,N' -tetraaceti c acid , pH 
7.0). Cell s we re disrupted using two 3-ml lue r-lock sylinges and a 
do uble-ended 25-ga uge emulsifying needle (Bolab Products, Lake Havasu 
C.ity, AZ). T he ce ll suspension w:~s p<~sscd be tween the two syringes in 25 
even strokes. The homogenate was centrifuged at 200 X g at 4 °C fo r 10 
n1in , :1nd the supe rn atant was then centrifuged at 40 .000 X g fo r 15 n1in . 
T he pellet was then centrifuged on a Pcrco ll gradient (1.04 5 g per ml) at 
40,000 X s; fo r 15 min. T he plasma membrane fraction was re moved and 
centrifuged at 100,000 X g fo r 30 m.in (Diaz et nl, 1988). 
Immunoblotting SCC-12F Plasma membranes were iso lated as out-
lined. Membrane protein (80 {J.g) was examined by sodium dodecyl 
sul f~1te-po l yacry lamide gel electro phorcs!s on a 4 - 20'/1, linear gradient ge l 
(Bio-Rad, luchmond, CA). After d ectropho resis, the prote ins were trans-
ferred to a Trans-Dlot polyvinylidene difluoride membrane (Bio-Rad) using 
the T rans-Blot SD semi-dry transfer ce ll (B io-Rad). Membranes were 
blocked ;md treated with either immune or pre-immune lgG ar 50 !J-g per ml 
fo r 1 h at room tempera ture. Membranes were washed and treated w ith goat 
anti-rabbit lgG co•tiugated to alkaline phosphatase (Sigma) used at a 1 :4000 
dilution. Second antibody was allowed to bind for 60 min at room 
temperature . T he membrane was washed and developed with Sigma Fast 
inso luble alkaline phosphatase substrate (Sigma) . 
hntnunofluorescence Immun ofluorescence was perfo1·med on three 
substrates, normal human sk.i n , monkey esophagus, and gu inea pig esoph-
agus , as prev io usly described (Bystryn and Sabo linski , 1986; Sabo linski cl nl, 
1987). T he substrates were 3-mo-o ld female Hartley guinea pig <:sophagus 
(C amm R esearch Lab Animals, Wayne NJ) , :~d ult male rhesus monkey 
esophagus (Flow Laboratories, McLean, VA), and normal human skin {tip 
of surg ica l excision of benign skin tum ors) . Fresh specimens were com-
pletely covered in OCT {Lab-Tek Products, D ivision of Miles , Napo•·vi.lle, 
fL) moun ting m edium, immediate ly frozen in liquid nitrogen , and kept at 
- 40°C until used. For usc, blocks of 0.4 X 0.4 em of each tissue were 
remounted togerl1er in OCT medium and 4-f-!.m sections were cut on a 
cryostat . Seria l dilutions of eithe r immune or pre-immune se rum was 
incubated w ith the substrate for 30 m.in at room temperature. T he sLides 
were was hed fo r 10 min with PBS. A 1:100 dilution of fluorescein- labe led 
goa t anti-rabbi t lgG (Organon Teknika, Durham , N C) was applied. T he 
sl.idc was incuba ted at room temperature for 30 min , washed fo r 10 min with 
·rBS, covered with about 0.2 ml of a po lyv in yl alcohol/glycerin mix ture, 
and examined with an Amc1ican Optical Fluoros tar m.icroscope equipped 
with model 2070 ve rtical illuminator containing a 1 00- w quartz haloge n 
lamp source with a B612 exciter fi lter, a 50-run dichroic mi rro r, and an 
06515 ba rrier fi lter, i.e., narrow band illumina tio n. 
Cytotoxicity Cytotoxicity was tested usiug a six-well multiwell plate 
(Falcon-LOP, Haledon , NJ) . W hen SCC-l 2F cell s were at about 75% 
confluence, the cell s from one 75-cm 2 fla sk were transferred to one six-well 
plate and used the next day. W ells were tre;Jted wi th 1.0 ml of a dilution of 
puri fied rabbit anti-kerarinocytc an tibody at room tcmperature fo r 30 min . 
Cell s were then washed and 1.0 ml of fresh human serum (as a source o f 
complement} was added and the cells incubated at 3 7°C as indicated . 
Cytotoxicity was meamred by the release of lactate dehydrogenase (LDH) 
enzymatic activi ty using a colorimetric assay (S igma). Tota l releasable LDH 
was estimated by treating cells w ith meli ttin (Sigma; I 00 f-l.g per ml , 1 .0 ml 
per well). 
Assay of Prostaglandin F 2 .. (PGF2a) PGF2" , was assayed by radioim-
munoassay (Amersha111, A rlington Heigh ts, l L) using the instructions 
p rovided with the assay k.it. Maximal production ofPGF2 a was estimated by 
treating the keratinocytes with mel.ittin (1 00 f-l.g per ml , 1.0 ml per well). 
Phosphatidylinositol-Specific Phospholipase C (PIPLC) Treatment 
ofSCC-12F SCC-12F cells were washed twice with bufre r in the absence 
o f fetal bovine serum. PIP.LC (l3oerhinger Mannhein1 , Indianapolis, IN ; 
0.125 U per well) was app lied and cells were incubated with PlPLC at 37°C 
for 30 min; 50% of the OAF and 75 'Y, of ihc CD 59 were rem oved by th is 
trca tn1 cnt . 
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Figure 1. Rabbit antiserum raised against SCC-12F pla sma mem-
brane vesicles binds to nativ e nonperme abilized cells. SCC-l2F ccUs 
were stained with an irrelevant m o use m onoclonal anti-C R.2 as a negative 
contro l o r 1:1. 0 dilu tio n of eith e r in1n1unc o r p rc-intnuulc rabbi t sen1111. 
Secondary anti bod y was phycoerythrin-labeled anti-ra bbi t lgG. Shown are 
FACS analyses using H b-5 m o use mo noclonal an ti body (· · · ·) and pre-
imm une (-- -) and immune (--) rab bi t sera. 
Compleme nt-Induced Vesicula tion of SCC-12F Complem ent-in-
duced vesiculatio n of the SCC-1 2F ce lls was measu red by using two 
techniques , Percoll gradients and m o lecular sieve chro m atography. For 
Pe rco ll grad ien ts, we used a va riation of the techniq ue we developed fo r 
lymphoblasto id cell s (Whitlow el nl, 1993 ) . .B ri efl y, ce lls we re labe led in the 
dark w ith a cationic m embrane- associated flu o rescent pro be, I ,l'-dihexa-
decyl-3,3 ,3 ',3 ' -tetramethylindocarbocyanine perchlorate fD iJC",(3); M o-
lecular Probes, Eugene, OR; 40 {-Lg per ml] tor 1 h at 37° in DM EM . Cells 
were washed tw ice and incubated w ith rabbi t an tibody (600 {-Lg per ml) in 
D ME M or w ith DME M alo ne fo r 30 rn.in o n ice. O ne milliliter o f a 1 ::tO 
dilu tion of fresh human serum w as then added, an d the ce ll s were incubated 
at 37°C fo r 30 min. T he supernata n t was removed and the vesicles were 
iso la ted by cen trifugatio n at 100,000 X g fo r JO min , washin g o nce with 
PBS, and then cen trifuging the vesicles over a 30°/1, Percoll gradient. T he 
grad ient frac ti ons were assayed for flu o rescen ce in a Fluoros km1 ll (f l o~v 
Labo ratories, McLean , V A) w ith an excitatio n of 544 nm and an emissio n of 
590 nm . Densi ty of the ficactions was estimated by using density m arker 
beads (Phannacia, Piscataway, NJ) in Pcrcoll gradients that were do ne in 
parall el w ith the exp erimental gradien ts . 
To m easure the presence o f the te rminal compl em ent pro teins o n 
ves icles, we used lllo lccular sieve chro nwtography to separate ves icles, 
which arc very large, fi·om un reaetcd comph:men t proteins o r complement 
pro te ins tha t have bo und to vitro nectin (S-protein ; Mo rgan el nl , ·t 987). T he 
excluded volume of the column will contil in the membrane vesicles, and 
unrcactcd mo no meric p ro tein, SC5b-9 complexes, and aggregated comple-
ment pro teins w ill be eluted in the included volume of th e co lumn . Purified 
human C8 was h1bcled wi th 125 1 by using Iodogcn (Pierce, .R.ockfo rd , IL). 
It was then added to e ithe r C8- de fi cient human serum o r C8-de fi cicnt 
se rum that had been heat-inactivated (56°C fo r 30 min; Quidcl, San D iego, 
C A). SCC-1 2F cell s were incuba ted with an tibody fo r 30 min icc and 
washed twice, and human serum or heat-inactivated st!rum was added. C~.: ll s 
were incubated at 3 7°C for 5 m in to allow fo rmation of the complemen t 
channels, the cells were washed tw ice, the m edium was replaced wi th 
D MEM w itho u t serum, and the cell s incubated :Jt 37°C for 60 nun . T he 
supcrna t:mt was rem oved and fractionated on the Scpharose 2B (Pharmacia) 
column (to tal vo lume 85 ml) . O nc-millilter fi·;1c ti ons were coll ected and 
radioactivi ty was n1 eas u.red. 
S t atis tical Analysis In the experiment com paring cytotoxicity of kera-
tinocytes wi th and w itho u t PIPLC trea tmcn r, d;Jta are represen ted as the 
m ean :!:: SD o f du plicate sam ples . Statistica l analys is was perfo rmed using 
the Student 's one-tailed t test . 
R ESULTS 
Characterization of the Rabbit A.nti-SCC-12F Antiserum 
T he rabbit anti-SCC12F antiserum w as characterized in two ways . 
W e first examined whether the antibody binds to nonpermea bi-
lized nonfixed cells. T he results o f FACS analysis using th e 
pre-immune and post-immunization sera are shown in Fig 1. T he 
immune serum clearl y binds to the cell s and detines a single 
population of the SCC-12F cells. Figure 2 show s the indirect 
immunofluorescence of the pre-imn1m1e and immune sera using 
hum an epidermi s as substrate . T he immune serum (Fig 2A ) binds 
to all layers o f the epidermis in an in te rcellular pattern . T here is 
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Figure 2 . R abbit a nti-SCC-12F binds to human epidermis in an 
intercellular pattern. Either im.rn une (n) o r pre-immune (b) serum at a 
dilu tion of ·t :50 was reacted wi th human epidermis. Skin specimens were 
then stained w i.th flu orescen t an ti-ra bbit anti body. 
minimal flu o rescence usin g the pt·e-immune seru m (F ig 2B) . ln 
data not shown , the immune serum binds in an intercellular pattern 
to guinea pig and m onkey esophagus. T hus the rabbit antiserum 
ntised aga inst th ese plasm a m embrane vesicl es recognizes an tigens 
present on the plasm a m embrane of SCC-1. 2F cells and shows 
cross-reactivity with epithelia fi·om human , monkey, an d guinea 
pig. W e perfo rmed western blotting against SCC-12F plasma 
m embrane antigens. T h e immune serum recognizes a band at 104 
kDa , bu t this mo lecule is also recognized by the pre-imm une serum 
(data not shown) . T hus the specific epi topes recognized by the 
immune seru m are destroyed by the treatm ent with sodimn dodecyl 
sulfate and merca ptoethan ol or there are m an y membrane pro teins 
recognized and , therefore, discrete bands are not visualized. We 
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Control t.H In act Fresh Serum 
F ig ure 3 . C3b is d eposited on SCC-12F ce lls by antibody plus 
nortna l human serum. SCC-l 2F cell s we re treated w ith l.O ml of 
an tibody (600 1'-g per ml) fo r 30 m in at room te m pera ture. Cells were 
washed twice w ith culture medium, and normal human se rum (20%) or 
heat-inactiva ted h uman serum as <1 source of complcmellt was added . Cells 
were incubated at 37°C for 15 min and then analyzed by FACS using 
anti-C3b monoclonal an ti bod y. Data arc expressed as me<m channel 
fl uo rescence. (I11 set) Original FACS analysis: H b-5 (nega tive control: · · · ·) , 
~H lnact (hea t-in activated serum ; - - - - ), and fres h human serum (-- ). 
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Figure 4. Removal of DAF with PIPLC increases C3 deposition. 
SCC-12F cells were treated with PIPLC (0.125 U per ml in DMEM) or 
DMEM alone for 30 min at 37°C. Cells were washed twice with serum-free 
DMEM. One milliliter of antibody (600 p.g per mJ) was added and cells 
incubated at 0°C for 30 min. Human serum (20%) was added and incubated 
for 15 min at 37°C. Cells were then analyzed with a FACS using 
Jnonoclonal anti- C3b. Data a_re expressed as n1ean c hanne l Auorescence. 
(f11se1) Original FACS analysis: HB-5 (negative control ; · · · ·) , DMEM 
(--- -) , and PIPLC (-. -). 
would predict that the antiserum would recognize multiple antigens 
as the vesicles contain multiple proteins, so that the 'lntisermn 
should be polyspecific as well as polyclonal. 
SCC- 12F Are Resistant to Complement Lysis We treated 
SCC-l2F keratinocytes with antibody and fresh normal human 
serum as a source of complement. In agreement with Norris et nl 
(1985), there was no lysis. (Highest concentration of rabbit anti-
body was 600 J.Lg per ml and highest concentration of no•·!nal 
human serum was 20%; data not shown). 
T he absence of cytotoxicity co uld be due to the lack of comp)e-
ment activation or to th e ability of SCC-12F to evade complement 
attack. To differentiate between these two possibilities, we mea-
sured the deposition of one of the early complement protein 
fragments, C3b, on the surface of SCC-12F. Figure 3 shows 
significant deposition of C3b on the cells in the presence of 
antibody and human serum but not in the presence of heat-
inactivated serum; thus, complement is activated and the ceUs are 
able to protect themselves from complement-mediated cytotoxic-
ity. In cells treated with human serum in the absence of an tibody, 
C3b deposition was about twice the amount deposited in the 
presence ofheat-i.nactivated serum, but only about one-tenth of the 
C3b deposited when the human serum is activated by the specific 
rabbit antibody (data not shown). This presumably represents a low 
level of complement activation by "natural antibodies" present in 
human serum or activation of the alternative complem ent pathway. 
Removal of Lipid-linked Complement Inhibitors Leads to 
Greater Complement Deposition and Increased Lysis Two 
important complement inhibitors are DAF and CD 59. Both of th ese 
molecules are glycan phosphatidylinositol-lin ked proteins and are 
therefore susceptible to cleavage by PIPLC. We would predict that 
treatment ofkeratinocytes with PIPLC would enhance complem ent 
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deposition and lysis. Figure 4 shows the deposition of C3b, and 
Fig 5 shows the deposition of C9 neoantigen (a measure of channel 
formation by CSb- 9) with ot· witho ut PIPLC treatment. As ex-
pected, there is significantly greater deposition ofC3b and CSb-9 in 
th e PIPLC-treated cells. Figure 6 shows that treatment of the cells 
w ith antibody and human serum resulted in no lys is above buB:e r 
control, but prior treatment of the cells with PrPLC leads to a small 
but statistica lly signific<lnt increase in homologous complement 
cytotoxicity . T here was no increase in cytotoxicity of the PIPLC-
treated cell s in the presence of either antibody or complement 
alone. 
Complement Induces the Production of Membrane Vesi-
cles That Contain the Terminal Complement Proteins In 
addition to membrane- bound inhibitors such as DAF and CD59, 
cells have the ability to remove complement channels either by 
vesiculation or endocytosis of membrane. We next examined 
wbetl1er the SCC-12F cells could vesiculate in response to com-
plement attack. We incorporated the fluorescen t lipid probe 
DiiC16(3) into the ceUs and treated the cells witl1 rabbit antibody 
alone, hum an serum alone, or antibody plus human serum. The 
supernatants were fractionated on a percoll gradient and the results 
are shown in Fig 7. As can be observed, activated complement 
releases signifi cantly rnore ves icles than serum or antibody alone, 
indi cating that active complement induces vesiculation. To deter-
mine whether the shed vesicles contained complement complexes, 
we treated keratinocytes w ith CS-deftcient serum to which 1 251-
labeled CS had been added. The C8-deficien t serum was eithe1: 
fi:es hly thawed or heat inactivated. The supernatants were removed 
and fi·actionated over a Sepharose 2B column . T he exclusion size of 
tlus column is 4 X 107 Da thus only very large particles such as lipid 
vesicles will be eluted in the void volume. T his technique has been 
used previously to isolate membrane vesicles induced by the 
terminal complement proteins (Morgan et n/, 1987). Only the 
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Figure 5. Removal of DAF with PIPLC increases C9 deposition. 
SCC-l2F cells were treated with PIPLC (0.:125 U per ml in DMEM) or 
DMEM alone for 30 min at 37°C. Cells were washed twice with serum-free 
DMEM. One milliliter of antibody (600 p.g per ml) was added and cells 
incubated at 0°C for 30 min. Humru1 serum (20%) was added :111d incubated 
for 15 min at 37"C. Cells were then analyzed with a FACS using 
monoclonal anti-C9 neoantigen. Shown a~e HB-5 (negative control; · · · ·), 
DMEM (--- -), and PJPLC (--). 
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compl ement prote in s in corporated into the lipid vesicles wi ll b e 
eluted in the void volume of the co lumn . As can be seen in Fig 8, 
compl ement induces the formation of membrane vesicles that 
contain the terminal comple m ent prote ins, as compared to h eat-
inactivated serum in w hich these complement-con ta in ing vesicles 
are absent. Thus compl ement induces the produ ction of membrane 
vesicles that contain terminal complem ent proteins. 
Complement Induces Keratinocyte Production of PGF2 "' 
We next investigated the abili ty of human compleme nt to induce 
PGF2 " production by SCC-12F. This eicosinoid was chosen be-
cau se it is known that another human squamous cell carcinoma cell 
line (SCC-1 3) synthesizes significant quantiti es of PGF20 in re-
sponse to m e littin (Rice and Levine, 1984). M elitrin incre;Jses 
m embrane permeability for calcium and activates phosphoHpase A 2 
(Co lotto eta /, 1986; Hermetter and Lakowicz , 1 986; Rou ssea u et al, 
1986) . Complement has bee n shown in many systems to cause 
e icosinoid re lease via the formation of transmembrane channels that 
allow ca lcium influx, subsequent phospholipase A2 activa tion, and 
eicosino id synthesis (Morgan , 1993) . Th us if keratinocytes syntiJe-
size prostaglandins in response to melittin , we reasoned that 
keratin ocytes might synthesize prostaglandins i.n response to com-
ple m ent. 
For these experiments we used amounts of fresh human seru m 
th at were noncytotox.i c and assayed mediato1· release as well as 
cyto tox.i city at 20 min after compl ement addition. As can be 
observed in Fig 9, the re is significant re lease of PGF2 " in the 
absence of cytotoxicity. Ma xi mal re le ase of PGF2 ., stimu lated by 
m elittin was 32 pg. Thus complement treatment of keratinocytes 
resulted in significant amounts of eicosinoid re lease in the absence 
of cell death. 
D ISCUSSION 
T he pllrpose of this investigation was to examine the e ffec ts of 
complement o n the SCC-12F cell line . We have chosen SCC-1.2F 
beca use of its phenotypic simi lari ty to primary keratinocytes (Rh ein-
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Figure 6. Removal of OAF and C0 59 leads to increased cytotox-
icity by human serum. SCC-12F cells were first sensitized wi th rabbit 
antibody (600 p.g per ml) for 30 min on icc. Cells were washed twice and 
treated with PIPLC (5 U per ml) or D ME M at 37°C for 30 min. Cells were 
washed twice and human serum (I U%) was added. Cells were incubated at 
3 7°C for 60 min and cytotoxicity was estim"ted by LDJ-1 release. Bars, B, 
DM,EM; Ab, <lntibody alone; AbC, antibody plus complement. Em11' bars , 
SO (n = 2). 
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Figure 7. Percoll gradient of contplement-induced m embrane ves-
icles. SCC-12F were l"bclcd with the membrane probl' Di!C",(3). The 
cells were treated with :tntibody alone (e) , hum"n serum alone (A), or 
antibody plus serum (.). The supernatant containing vesicles was centri-
fuged o n a Pcrco ll gradient and the presence of n1 cn1branc vesicles \ V::ts 
assayed by fluorescence. The position of density standards wi rl : their dcnsiry 
in grams per ml (p) arc shown as t . 
wa ld and Beckett, 1980, 198 1) . We ha ve deve loped a system in 
which the lytic and n o nlytic effects of complement can be mea-
sured . In agreem ent with the work of Norri s et nl, we have found 
that human keratinocytes are rem arka bly resistant co complemen t 
attack (Norris et nl, 1985). W e demonstrate that, in the presence of 
specific ;mt.ibody and human serum , compl ement is activated but 
that the cells resist compl em ent-mediated cytotoxicity. The g lycan 
phosphatidyl.inositol-lin ked molecules OAF and CD59 are partia iJ y 
responsibl e for the ability of cells to defend themselves from 
compl em ent, beca use their re moval by PIPLC leads to in creased 
d eposition of complem e nt and inc reased complem ent-mediated 
cytolysis. The actual increase in complement-mediated cytotoxicity 
is small. This could re fl ect the fact that DAF and CDS9 were 
reduced but not totally removed, but cells have num erous tech-
niqu es to circumvent complem ent attack s;.~ch as the vesiculation of 
the damaged m embrane, and thus for optimal complement cyto-
toxicity, several of these mechanism s may need to be disabled. 
We d emonstrate tha t SCC-l2F do produ ce m embran e ves icles in 
response to complem e nt attack . We h ave previously shown th at 
puromycin (an inhibitor of prote in synthesis) increases susceptibility 
of a monocyte / macrophage cell line to comple m ent by redu cing 
the abi li ty of the cells to e lintinate complem ent chann els (Ramm et 
a/, 1984). Thus the observation ofNorJ"is et nl (1.985) that rrea011ent 
of ke ratinocytes with cyclohex.imide increases their su sceptibili ty to 
lys is may be a result of the decreased ability to e ithe r shed or 
e nd ocytose ch annels. 
We assayed the ability ofSCC-12F cells to produce the PGF~., in 
response to complem ent attack. T he SCC-12 ce lls produce signif-
icant quantities of the e icosinoid under condi tio ns in which there is 
no lys is. 
The most li kely m echanism of complem ent-induced e icosinoid 
synthesis is via the formation of transmembran e channels by the 
terminal complement proteins CS b-9. Many ceLls h ave the abitity to 
synthesize prostaglandins and leukotrienes after ch annel formation 
due to the activation of phospho lipase A 2 , thereby liberating 
arachidonic ac id and lea ding to eicosinoid synthesis and release 
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Figure 8. Gel exclusion chromatography of complement-induced 
membrane vesicles. Antibody-sensitized SCC-12F cells were incubated 
with 125!-labeled C8 in fresh C8-deftcient serum (e) or heat-inactivated 
CS-deficient serum (•) at 37°C for 5 min to allow channel fonnation. T he 
cells were then washed, fresh serum-free medium was added, and the ceUs 
were allowed to vesiculate for 1 h. The supernatant was collected and 
fractionated on an 85-ml Sepharose 2B column. Radioactivity in l-ml 
fractions was measured. Void volume (V0 ) is shown. 
(Morgan, 1993) . Tl1e other possible mechanism of complement-
induced eicosinoid release is via the production of the anphylatox-
in s C3a and C5a, but keratinocytes have not been reported to have 
anaphylatoxin receptors, leaving channel formation as the most 
like ly trigger for prostaglandin release (Elder et al, 1991; Haviland 
et n/, 1995). 
Our demonstration that SCC-12F produce PGF2 " and membrane 
vesicles in response to complement attack is important in under-
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Figure 9. Complement induces release ofPGF2 ,.. SCC-12F cells were 
treated with various dilutions of antibody at room temperature for 30 min . 
Cells were washed twice and normal human serum was added as a source of 
complement. Supernatants were removed after 20 min and assayed for 
cytotoxicity by LDH release (0 ) and PGF2 " release (e). 
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standing the role of complement in skin disease because it demon-
strates that complement induces nonlytic biologic responses in skin. 
In virtually all diseases in which complement deposition occurs, cell 
death is not a prominent feature. Thus one key to understanding the 
pathogenic role of the complement system in skin disease is to 
understand its nonlytic effects. For example, formation of comple-
ment channels on glomerular epithelial cells leads to the release of 
interleukin (IL)-1. The actual mechanism of IL-1 release is not 
!mown, but a similar phenomenon may occur with keratinocytes. It 
is known that keratinocytes synthesize and release IL-1, bu t the 
mechanism of release is not known (Sauder, 1991). Keratinocytes 
are known to synthesize many cytokin es in addition to IL-1, 
including other interleukins, colony-stimulating factor, growth 
f.'lctors, and interferon-a (Sauder, 1991). The role of complement 
in the release of these mediators has not been investigated, but our 
studies emphasize the possibility that cytokines and other eicosi-
noids may be released in response to complement. 
These studies also have therapeutic implications. Soluble com-
plement inhibitors such as soluble complement receptor-1 and 
anti-CS monoclonal antibody have b een shown to be effective in 
the treatment of eardiac reperfusion injury and inm1une complex 
arthritis in experimental systems (Weisman et nl, 1990; Wang et nl, 
1995). These soluble inhibitors may prove to he useful in inflam-
matory skin disease. We have recently shown that on erythrocytes 
the sialylated molecules glycophorin and gangliosides act as recep-
tors for C5b6 and that adding these molecules to the fluid phase 
competes with the erythrocyte for complement deposition and 
decreases lysis (Marshall eta/, 1996). If similar receptors are present 
on keratinocytes, it may be possible to treat inflammatory skin 
disease with soluble derivatives of these receptors. 
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